Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.
Ridolfi L, de Rosa F, Ridolfi R, Gentili G, Valmorri L, Scarpi E, Parisi E, Romeo A, Guidoboni M. Ridolfi L, et al. Among authors: ridolfi r. J Transl Med. 2014 Sep 23;12:262. doi: 10.1186/s12967-014-0262-6. J Transl Med. 2014. PMID: 25245327 Free PMC article. Clinical Trial.
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.
Ridolfi L, Petrini M, Granato AM, Gentilcore G, Simeone E, Ascierto PA, Pancisi E, Ancarani V, Fiammenghi L, Guidoboni M, de Rosa F, Valmorri L, Scarpi E, Nicoletti SV, Baravelli S, Riccobon A, Ridolfi R. Ridolfi L, et al. Among authors: ridolfi r. J Transl Med. 2013 May 31;11:135. doi: 10.1186/1479-5876-11-135. J Transl Med. 2013. PMID: 23725550 Free PMC article.
Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study.
de Rosa F, Ridolfi L, Ridolfi R, Gentili G, Valmorri L, Nanni O, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Riccobon A, Parisi E, Romeo A, Turci L, Guidoboni M. de Rosa F, et al. Among authors: ridolfi r, ridolfi l. J Transl Med. 2014 Jul 22;12:209. doi: 10.1186/1479-5876-12-209. J Transl Med. 2014. PMID: 25053129 Free PMC article. Clinical Trial.
Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis.
Ridolfi L, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Scarpi E, Guidoboni M, Migliori G, Sanna S, Tauceri F, Verdecchia GM, Riccobon A, Valmorri L, Ridolfi R. Ridolfi L, et al. Among authors: ridolfi r. Clin Dev Immunol. 2010;2010:504979. doi: 10.1155/2010/504979. Epub 2010 Sep 27. Clin Dev Immunol. 2010. PMID: 20936106 Free PMC article. Clinical Trial.
Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome.
Ridolfi L, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Brolli C, Selva M, Scarpi E, Valmorri L, Nicoletti SV, Guidoboni M, Riccobon A, Ridolfi R. Ridolfi L, et al. Among authors: ridolfi r. Melanoma Res. 2011 Dec;21(6):524-9. doi: 10.1097/CMR.0b013e32834b58fa. Melanoma Res. 2011. PMID: 21909041
MicroRNAs and dendritic cell-based vaccination in melanoma patients.
de Rosa F, Fanini F, Guidoboni M, Vannini I, Amadori D, Ridolfi R, Ridolfi L, Fabbri M. de Rosa F, et al. Among authors: ridolfi r, ridolfi l. Melanoma Res. 2014 Jun;24(3):181-9. doi: 10.1097/CMR.0000000000000058. Melanoma Res. 2014. PMID: 24638153 Review.
Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience.
de Rosa F, Ridolfi L, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Bulgarelli J, Framarini M, Tauceri F, Migliori G, Brolli C, Gentili G, Petracci E, Nanni O, Riccobon A, Ridolfi R, Guidoboni M. de Rosa F, et al. Among authors: ridolfi r. Melanoma Res. 2017 Aug;27(4):351-357. doi: 10.1097/CMR.0000000000000356. Melanoma Res. 2017. PMID: 28654547
Ipilimumab in advanced melanoma: reports of long-lasting responses.
Farolfi A, Ridolfi L, Guidoboni M, Nicoletti SV, Piciucchi S, Valmorri L, Costantini M, Scarpi E, Amadori D, Ridolfi R. Farolfi A, et al. Among authors: ridolfi r, ridolfi l. Melanoma Res. 2012 Jun;22(3):263-70. doi: 10.1097/CMR.0b013e328353e65c. Melanoma Res. 2012. PMID: 22516968
118 results